bioeq / Bioeq

Robots.txt Information

Robot	Path	Permission
GoogleBot	/	✔
BingBot	/	✔
BaiduSpider	/	✔
YandexBot	/	✔
# START YOAST BLOCK # --------------------------- User-agent: * Disallow: Sitemap: https://bioeq.ch/sitemap_index.xml # --------------------------- # END YOAST

Meta Tags

Title	Bioeq
Description	Home About us Careers Publications Contact About Us Bioeq AG is a Swiss biopharmaceutical joint venture between Polpharma Biologics Group and Formycon and
Keywords	N/A

Server Information

WebSite	bioeq.ch
Host IP	194.124.232.65
Location	Switzerland

Related Websites

                        Site
                        Rank
                    

More to Explore

bioeq.ch Valuation

US$802,766

Last updated: 2023-05-17 12:11:01

bioeq.ch has Semrush global rank of 13,184,807. bioeq.ch has an estimated worth of US$ 802,766, based on its estimated Ads revenue. bioeq.ch receives approximately 92,627 unique visitors each day. Its web server is located in Switzerland, with IP address 194.124.232.65. According to SiteAdvisor, bioeq.ch is safe to visit.

Traffic & Worth Estimates

Purchase/Sale Value	US$802,766
Daily Ads Revenue	US$742
Monthly Ads Revenue	US$22,231
Yearly Ads Revenue	US$266,766
Daily Unique Visitors	6,176
Note: All traffic and earnings values are estimates.

DNS Records

Host	Type	TTL	Data
bioeq.ch.	A	3599	IP: 194.124.232.65
bioeq.ch.	NS	3600	NS Record: specter.mva-n.net.
bioeq.ch.	NS	3600	NS Record: mulgore.mva-n.net.
bioeq.ch.	MX	3600	MX Record: 10 d306059.a.ess.de.barracudanetworks.com.
bioeq.ch.	MX	3600	MX Record: 20 d306059.b.ess.de.barracudanetworks.com.
bioeq.ch.	TXT	3600	TXT Record: v=spf1 include:spf.ess.de.barracudanetworks.com include:spf.protection.outlook.com -all
bioeq.ch.	TXT	3600	TXT Record: mrk5gpbfs9nxcfcgz5pm85yvbzrwfhkd

HtmlToTextCheckTime:2023-05-17 12:11:01

Home About us Careers Publications Contact About Us Bioeq AG is a Swiss biopharmaceutical joint venture between Polpharma Biologics Group and Formycon and is based in Zug. We license, develop and commercialise a biosimilar, which is a successor product of Lucentis® (ranibizumab), a successful branded biopharmaceutical. We are a young and dynamic company, supported by an international network of experts. Bioeq AG out-licenses its products to established international pharmaceutical companies who ensure local distribution in each territory. Careers We are currently not hiring Publications Press Release Bioeq AG – EC Approval FYB/Ranivisio 29.08.2022 Press Release Bioeq AG – FDA approves CIMERLI, the first biosimilar interchangeable with Lucentis 03.08.2022 Press Release Bioeq AG – GRANT OF MARKETING AUTHORISATION IN UK 17.05.2022 Press Release Bioeq AG and MS Pharma 14.12.2021 Press Release Bioeq AG and Teva 28.06.2021 Press Release Bioeq AG and Coherus 06.11.2019 Contact Bioeq AG

HTTP Headers

HTTP/1.1 301 Moved Permanently
Server: nginx
Date: Fri, 25 Mar 2022 08:47:51 GMT
Content-Type: text/html
Content-Length: 162
Connection: keep-alive
Location: https://bioeq.ch/

HTTP/2 200 
server: nginx
date: Fri, 25 Mar 2022 08:47:51 GMT
content-type: text/html; charset=UTF-8
vary: Accept-Encoding
x-powered-by: PHP/7.4.28
link: ; rel="https://api.w.org/", ; rel="alternate"; type="application/json", ; rel=shortlink
set-cookie: pll_language=en; expires=Sat, 25-Mar-2023 08:47:51 GMT; Max-Age=31536000; path=/; secure; SameSite=Lax

bioeq.ch valuation and analysis